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ABSTRACT
BACKGROUND: People with no previous cardiovascular events or car-
diovascular disease represent a primary prevention population. The 
benefits and harms of treating mild hypertension in primary prevention 
patients are not known at present. This review examines the existing 
randomized controlled trial (RCT) evidence.
OBJECTIVE: Primary objective: To quantify the effects of antihyperten-
sive drug therapy on mortality and morbidity in adults with mild hyper-
tension (systolic blood pressure (BP) 140-159 mmHg and/or diastolic BP 
90-99 mmHg) and without cardiovascular disease.
METHODS: 
Search: We searched CENTRAL (2011, Issue 1), MEDLINE (1948 to May 
2011), EMBASE (1980 to May 2011) and reference lists of articles. The Co-
chrane Database of Systematic Reviews and the Database of Abstracts of 
Reviews of Effectiveness (DARE) were searched for previous reviews and 
meta-analyses of anti-hypertensive drug treatment compared to placebo 
or no treatment trials up until the end of 2011.
Selection criteria: RCTs of at least 1 year duration.
Data collection and analysis: The outcomes assessed were mortality, 
stroke, coronary heart disease (CHD), total cardiovascular events (CVS), 
and withdrawals due to adverse effects.
MAIN RESULTS: Of 11 RCTs identified 4 were included in this review, with 
8,912 participants. Treatment for 4 to 5 years with antihypertensive drugs 
as compared to placebo did not reduce total mortality (RR 0.85, 95% CI 
0.63, 1.15). In 7,080 participants treatment with antihypertensive drugs 
as compared to placebo did not reduce coronary heart disease (RR 1.12, 
95% CI 0.80, 1.57), stroke (RR 0.51, 95% CI 0.24, 1.08), or total cardiovascu-
lar events (RR 0.97, 95% CI 0.72, 1.32). Withdrawals due to adverse effects 
were increased by drug therapy (RR 4.80, 95% CI 4.14, 5.57), ARR 9%.
AUTHORS’ CONCLUSIONS: Antihypertensive drugs used in the treat-
ment of adults (primary prevention) with mild hypertension (systolic 
BP 140-159 mmHg and/or diastolic BP 90-99 mmHg) have not been 
shown to reduce mortality or morbidity in RCTs. Treatment caused 9% 
of patients to discontinue treatment due to adverse effects. More RCTs 
are needed in this prevalent population to know whether the benefits 
of treatment exceed the harms. 
This is the abstract of a Cochrane Review published in the Co-
chrane Database of Systematic Reviews (CDSR) 2012, issue 8, DOI: 
10.1002/14651858.CD006742.pub8 (http://onlinelibrary.wiley.com/
doi/10.1002/14651858.CD006742.pub2/abstract). For full citation and 
authors details see reference 1.
The full text is freely available from: http://cochrane.bvsalud.org/co-
chrane/show.php?db=reviews&mfn=4030&id=CD006742&lang=pt&d
blang=&lib=COC&print=yes#
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COMMENTS
The capacity to lower most hypertensive individuals’ blood pressure 
already exists, with minimal adverse effects. However, the debate re-
garding therapy has shifted from whether lowering blood pressure is 
beneficial to the relative benefits and risks of individualized antihyper-
tensive medications and their long-term effects on cardiovascular dis-
ease and chronic renal disease outcomes, especially for patients with 
mild hypertension.
On the basis of extensive epidemiological and observational data, car-
diovascular risk progressively increases, starting from blood pressure 
levels as low as 115/75 mmHg.1 On the other hand, some prospective 
trials2-5 have shown that the benefits from lowering blood pressure be-
low 130/80 mmHg still appear uncertain in groups such as the elderly, 
those with coexisting cardiovascular disease, chronic renal disease or di-
abetes mellitus, and those with other forms of high cardiovascular risk. 
Furthermore, the ACCORD trial6 showed that the additional medication 
required to achieve lower blood pressure goals may be associated with 
additional adverse effects. 
A study in the most recently published Cochrane Database of System-
atic Reviews (2012)7 questioned the risks and harm of pharmacotherapy 
for mild hypertension among primary prevention patients, because 
such information is still unavailable for this particular group. Based 
on four randomized controlled trials, the authors7 pointed out that, 
in comparison with placebo, antihypertensive drugs administered to 
8,912 participants did not reduce total mortality after four to five years 
of follow-up, and that in 7,080 participants, pharmacological treatment 
failed to reduce the incidence of coronary heart disease, stroke or total 
cardiovascular events, in comparison with placebo. Moreover, patient 
withdrawals due to side effects were substantially increased by drug 
therapy. From these conflicting data, two questions arise. Firstly, at what 
blood pressure level should patients be kept? Secondly, how should 
they be treated, especially those with mild hypertension? 
In our opinion, it is almost impossible to develop a prospective trial com-
paring pharmacological therapy to placebo among mildly hypertensive 
patients undergoing primary prevention to answer the above ques-
tions. In order to have a number of cardiovascular events or deaths large 
enough to achieve statistical significance in this low-risk population, a 
huge number of individuals would need to be enrolled and followed 
up for decades. Moreover, leaving thousands of patients without treat-
ment for such a long time would also be a matter of concern. Although 
such an approach might be considered to be overly conservative, the 
issues are complex and mixed information becomes confusing in clinical 
practice. Based on data from epidemiological and prospective studies, as 
mentioned earlier, we think that the most reasonable approach at pres-
ent would be to have a general blood pressure goal of lower than 140/90 
mmHg among mild and low-risk hypertensive individuals, and always 
to start with non-pharmacological therapy. For cases requiring lower 
targets or that are unresponsive to lifestyle modifications, the therapy 
should be individualized on the basis of clinical judgment.   
Agostinho Tavares. Associate Professor and Head, Discipline of Nefrol-
ogy, Universidade Federal de São Paulo — Escola Paulista de Medicina 
(Unifesp-EPM), São Paulo, Brazil.
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